A New Stage in US Market Strategy

Utilize M&A to further build capability and expand presence

November 4, 2021

Shinjiro Sato

President and CEOTerumo Corporation

Safe Harbor for Forward-Looking Statements and Use of Document
Among the information that Terumo discloses, the forward-looking statements including financial projections arebased upon our assumptions using information available to us at the time and are not intended to be guarantees
of future events or performance. Accordingly, it should be noted that actual results may differ from those
forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to,changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state ofcompetition.
The market share information in this presentation is partly derived from our own independent research.
Information about products (including products currently in development) which is included in this material is notintended to constitute an advertisement or medical advice.
Terumo Corporation
Investor Relations Dept.
E-mail: kouhou_terumo01@terumo.co.jp©TERUMO CORPORATION

2 / 11TA* Achieves Full Lineup of Aortic Products in the US*Terumo Aortic

Bolton Stent Graft
Interventional therapy

HybridSurgery

ThoracicStent Graft
RelayProThoracic
Surgical Graft
Gelweave

Abdominal
Stent Graft
TREO

Abdominal
Surgical Graft
Gelsoft©TERUMO CORPORATION

3 / 11Hybrid stent graftThoraflex Hybrid**Launch expected next year

Growth of US Business & Acquisitions (from 2000)
HOS (US)(100M JPY)
2,000

Aortica (US)1,800

Bolton (US)

1,600

TBCT

Angio-Seal (US)

1,400

GH

Sequent (US)

1,200’99) Cardiovascular
1,000 Div. of 3M (US)MicroVention (US)CaridianBCT (US)

800C&V

600

Vascutek

400
2000
FY 0001020304050607080910111213141516171819*Sales: North America, inc. Canada©TERUMO CORPORATION

4 / 112021(Expected)

20 Years of C&V Business in the US Market
US market C&V sales trend (Access vs Therapeutic)*(100M JPY)
1,400

1,200

Bolton (US)CV

Sequent (US)

1,000

TA

Angio-Seal (US)Neuro

800’99) Cardiovascular
600 Div. of 3M (US)TIS(ex. Access)MicroVention (US)TIS sales
go direct

400Access

Vascutek

2000

Therapeutic

FY 000102030405060708091011121314151617181920*Sales: North America, inc. Canada©TERUMO CORPORATION

5 / 11Improved Status in the US
Competitor Sales (2019)

Sales Growth (2011-2019)

Medtronic

Edwards

J&J

B.D.

Stryker

TerumoB.D.

AbbottBostonIntutive

AbbottStryker

ZimmerZimmerBaxterMedtronic

Intutive

BostonEdwards

Olympus

Olympus

J&J#12Terumo02,000164%

Baxter

4,000

6,000

8,000

10,00012,00014,00016,000(M USD)

-50%

0%

50%

100%

150%

200%

250%

300%

Calcurated by Terumo from earnings info of each company

Presence with Main Product Line (market share)
TIS Access*Brain Aneurysm*

Oxygenator

Surgical Stent#1#1 to #2

#1

#1

#1

MRG2019
Calculated by Terumo*1: Angiographic Catheter, Guidewire, Sheath Introducer*2: Embolization Coils, WEB, Flow Diverter Stent©TERUMO CORPORATION

Blood Automatedcollection

6 / 11

Trajectory of Sustainable Growth Centered onAcquisitions outside Japan
‘98

‘00

‘02

‘06

‘11

SPC* entry

TBCTBT*

‘21

‘16

TMC

GHP*
CV

TCVS

TERUMOTIS AccessAngio-Seal

TAVAK
Relay, TREOMVWEB※SPC: Source Plasma Collection※BT: Blood Transfusion※GHP: General Hospital Products©TERUMO CORPORATION

7 / 11Management Capability, Value Chain Evolution
Until the late 90s

Now

Simply produce and sell items
that already sold in Japan

R&D → mfg/sale → improvement
Products/services that win in the US
Terumo Cardiovascular
Systems (TCVS) Corp.

Terumo BCT, Inc

Business HQ
R&D, production
R&D

MicroVention, Inc.

Japan
launchClinical
Trial

Marketing

Regulatory

Manufacturing

Sales

Quality

Improvement
ExpansionDevelopment

Marketing

Regulatory

Manufacturing

Sales

Quality

Improvement
Expansion

Offer an end-to-end value chain
centered in US sites

3 barriers to US entry: IP,Regulatory, Sales network©TERUMO CORPORATIONClinicalTrialProduction

8 / 11

US market Growth Potential in GS26**Growth Strategy 26 (next mid- to long-term strategy)• Promote radial access to treat entire body (TIS access products for peripheral,oncology, neurovascular)

Cardiac andVascular• Expand TIS products (therapeutic & access) for peripheral, oncology• Expand therapeutic devices for stroke (ischemic/hemorrhagic)• TA full deployment in aortic aneurysm treatment market

Blood and Cell
TechnologiesGeneralHospital©TERUMO CORPORATION• Build plasma innovation (source plasma market) business• Promote whole blood automation system• Bring high-added-value products to selected markets indlucing B2B

9 / 11

Potential in the US to Expand Solution Business
The market where new products are born‖US-style Development
C&V
TBCT＋

Medical Institutions

Medical cost
efficiency
Medical Professionals

Best solutions
w/DX

Healthcare
accessGH

Patients
QOL
improvement
Pharma &Biotechnology
companies©TERUMO CORPORATION

10 / 11

Era of Fully Leveraging Overall Group Strengths
What (Aims)

Strengthen Mgmt. Platform (Themes)(1) Account managementAdapt to changing purchasing structures (GPO/IDN)(2) DX in business development

Differentiate by individualized medicine using digital technology(3) Enhance brandStrengthen Terumo brand messaging(4) Production & SCM optimization

Optimize network across businesses and share best practices(5) Procurement optimization

Work toward joint regional purchasing, other difficult themes(6) IT infrastructure (DX in operations)Global work standardization and consolidation©TERUMO CORPORATION

11 / 11